Cytokinetics Secures Up to $575M from Royalty Pharma, Dimming Buyout Hopes
Originally Published 1 year ago — by STAT
Cytokinetics CEO Robert Blum faces criticism for raising $500 million at $51 per share, which devalues the stock and aficamtem's potential. Additionally, the decision to revive the heart failure drug omecamtiv and the unfavorable terms of the Royalty Pharma loan are seen as poor management choices.